One Stop Shopping: Michigan Mall Customers Have An Affordable Mammogram OptionThe Breast Cancer Site
Recent studies suggest that only about 40 percent of women over the age of 40 have an annual mammogram to screen for breast cancer. A group of Michigan radiologists is hoping to change that statistic and make mammograms more accessible to women by offering the screenings in an unlikely location: the mall.
Housed in a 832-square-foot office in the lower level of RiverTown Crossings Mall in Grandville, Michigan, Clarity Screening Mammography states it offers screening mammograms without the need for a prescription or an appointment. The office is owned by three board-certified radiologists who have 55 years of combined mammography experience.
Women visiting the Clarity Screening Mammography suite in RiverTown Crossings Mall won’t feel like they’re in a doctor’s office. Instead, they can expect a private, spa-like environment with opaque windows to prevent other mall customers from seeing who is in the waiting room.
Having a screening mammogram at this first-of-its-kind clinic won’t take much time or money away from shopping. According to MLive, the breast cancer screening takes only 15 minutes and costs a reasonable $225, compared to other clinics that may charge anywhere from $300 to $500. To offset these costs, Clarity Screening Mammography accepts most health insurance plans.
After the screening, WZZM13 states that Clarity Screening Mammography follows up with both the woman and her primary care physician regarding the results. Every woman who has a screening mammogram should discuss her individual results with a trusted health care provider.
By providing screening mammograms in a convenient location on a walk-in basis, Clarity Screening Mammography hopes to increase the number of women over age 40 who have annual mammograms. However, some insurance companies want to restrict women’s access to mammograms. To make your voice heard, sign the petition at The Breast Cancer Site, and tell state insurance regulators to stop insurance companies from restricting access to this important screening tool.